

---

Poster

## [P26-7] P26-7: Oncologic drugs (3): Pharmaometrics, PK/PD, special population

Chair: Shiro Fukumori, Japan

Tue. Sep 26, 2017 12:30 PM - 1:30 PM Annex Hall (1F)

---

(Tue. Sep 26, 2017 12:30 PM - 1:30 PM Annex Hall )

## [P26-7-7] A case of gemcitabine and cisplatin chemotherapy in a patient with metastatic urothelial carcinoma under hemodialysis

Taisuke Ezaki<sup>1</sup>, Kazuhiro Matsumoto<sup>2</sup>, Shinya Morita<sup>3</sup>, Kazunobu Shinoda<sup>4</sup>, Ryuichi Mizuno<sup>5</sup>, Eiji Kikuchi<sup>6</sup>, Mototsugu Oya<sup>7</sup> (1.Saitama City Hospital, 2.Keio University School of Medicine, 3.Keio University School of Medicine, 4.Keio University School of Medicine, 5.Keio University School of Medicine, 6.Keio University School of Medicine, 7.Keio University School of Medicine)

Keywords: hemodialysis, chemotherapy, gemcitabine, cisplatin, urothelial carcinoma

### Background

GC (gemcitabine and cisplatin) chemotherapy is now preferred as the first line chemotherapy for urothelial carcinoma. The optimal doses and schedule of GC chemotherapy for patients under hemodialysis have not been fully determined yet. This is a report in which the plasma concentrations of gemcitabine and cisplatin were monitored during the therapy.

### Methods

A 70-year-old male under hemodialysis experienced the recurrence of urothelial carcinoma, and received salvage GC chemotherapy. The plasma concentrations of gemcitabine and free / total cisplatin were monitored to assure the safety during the chemotherapy.

### Results

The patient completed the chemotherapy with no severe side effects except for grade 3 bone marrow toxicity, and CT scan demonstrated partial response after 8 cycles.

### Conclusions

The results indicate that our GC chemotherapy regimen for hemodialysis patients is comparatively safe and effective, and can be followed as one of the therapeutic options.